NASDAQ · PLUR
Healthcare · Biotechnology
$1.25
Down-$0.12 (-8.76%)
Updated Sep 11, 2026, 12:43 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
PLUR closed at $1.25 after 20 trading sessions, down 24.76% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $1.34 | $1.34 | $1.24 | $1.25 | 25.48K |
| Sep 9, 2026 | $1.26 | $1.39 | $1.25 | $1.37 | 7.4K |
| Sep 8, 2026 | $1.36 | $1.3997 | $1.27 | $1.27 | 17.55K |
| Sep 4, 2026 | $1.41 | $1.4515 | $1.31 | $1.36 | 15.45K |
| Sep 3, 2026 | $1.44 | $1.4504 | $1.25 | $1.37 | 14.04K |
| Sep 2, 2026 | $1.5099 | $1.52 | $1.38 | $1.42 | 37.73K |
| Sep 1, 2026 | $1.44 | $1.464 | $1.44 | $1.46 | 3.68K |
| Aug 31, 2026 | $1.53 | $1.57 | $1.41 | $1.47 | 48.91K |
| Aug 28, 2026 | $1.52 | $1.6289 | $1.46 | $1.53 | 24.33K |
| Aug 27, 2026 | $1.51 | $1.6449 | $1.45 | $1.53 | 102.1K |
| Aug 26, 2026 | $1.63 | $1.63 | $1.48 | $1.48 | 96.49K |
| Aug 25, 2026 | $1.57 | $1.6699 | $1.57 | $1.66 | 18.95K |
| Aug 24, 2026 | $1.68 | $1.71 | $1.5499 | $1.56 | 38.24K |
| Aug 21, 2026 | $1.70 | $1.84 | $1.70 | $1.71 | 4.61K |
| Aug 20, 2026 | $1.7499 | $1.77 | $1.72 | $1.77 | 15.21K |
| Aug 19, 2026 | $1.63 | $1.83 | $1.63 | $1.76 | 34.61K |
| Aug 18, 2026 | $1.60 | $1.63 | $1.59 | $1.63 | 10.61K |
| Aug 17, 2026 | $1.63 | $1.67 | $1.55 | $1.60 | 48.91K |
| Aug 14, 2026 | $1.6625 | $1.72 | $1.60 | $1.60 | 2.99K |
| Aug 13, 2026 | $1.60 | $1.67 | $1.60 | $1.6614 | 1.27K |
The latest Smart Investors Daily articles mentioning PLUR.
PLUR research
Company profile and research snapshot.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 2, 2025 | Alliance Global Partners | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 27, 2026
Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri"), a biotechnology company, leveraging its proprietary three-dimensional ("3D") cell expansion platform across two principal business verticals: (i) Human
Yahoo · Aug 17, 2026
Pluri's majority-owned food-tech company adds aquatic cell biology, animal-component-free media capabilities and a European scientific presenceEver After Foods secures an additional $2 million strategic investment supporting ongoing platform development and commercialization activities. HAIFA, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri”), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across ther
Yahoo · Aug 17, 2026
Acquisition Adds Complementary Technologies, Scientific Expertise and a European Center of Excellence to Strengthen EAF's Platform for the Food and Ingredient IndustryHAIFA, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Ever After Foods (EAF) today announced the strategic acquisition of Fishway, representing an important milestone in the company's long-term strategy to expand its industrial protein manufacturing platform through the integration of complementary technologies and scientific capabiliti
Yahoo · Jul 28, 2026
UK regulatory registration supports commercial launch of regenerative aesthetics portfolio in a market with an estimated size of ~$900 million annually, and strengthens the foundation for broader international expansion HAIFA, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announc
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PLUR.
